|Mr. Michael A. Sherman||CEO, Pres & Director||1.11M||N/A||1966|
|Mr. Michael T. Andriole M.B.A.||Chief Bus. Officer, Sec. & CFO||657.35k||N/A||1973|
|Dr. Allen S. Melemed M.B.A., M.D.||Chief Medical Officer||508.92k||N/A||N/A|
|Mr. David Jakeman||Exec. Director of Fin. & Accounting and Principal Accounting Officer||N/A||N/A||1977|
|Dr. Roy W. Ware||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
|Dr. Randall Lanier||Chief Science Officer||N/A||N/A||N/A|
|Ms. Michelle LaSpaluto||VP of Strategic Planning & Investor Relations||N/A||N/A||N/A|
|Dr. Michael A. Alrutz||Sr. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1970|
|Dr. Joshua E. Allen||Chief Technology Officer of Imipridones||N/A||N/A||N/A|
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Chimerix, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 8; Compensation: 9.